Global Cardiac Biomarkers Market to Reach $2.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

Rising cases of cardiovascular diseases and ageing population have served as primary growth drivers for cardiac biomarkers market, one of the fastest growing sectors in the clinical immunodiagnostics market. The fast growing BNP & NT-proBNP assay test for congestive heart failure, is the other significant growth driver for the global cardiac biomarkers market. With the number of people affected with cardiovascular diseases reaching 30 million a year worldwide, the global market for cardiac biomarkers is set to reach $2.6 billion by 2015.

Cardiac Biomarkers: A Global Strategic Business Report

The healthcare sector worldwide place utmost importance on fast and accurate identification of heart problems, in order to initiate timely and accurate treatment at the earliest. The market for cardiac biomarkers, which helps in detecting the severity and existence of heart problems at the earliest, is expected to witness steady growth. The Point-of-Care Testing (POCT) platform is more popular among the new breed of physicians who give prime importance on faster resulting and mobility; while experienced physicians rely more on Laboratory Testing platform that is perceived to be more accurate and provide detailed analysis.

The United States is the largest market worldwide, followed by Europe as the second largest regional market. By Assay Test type, Cardiac troponin assay test represents the largest segment, and B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) assay test represent the second largest and the fastest growing test segment. By location type, Laboratory Testing segment is the leading segment, while the Point-of-Care Testing segment is growing at a faster pace.

Key participants in the global marketplace include Siemens Healthcare Diagnostics, Inverness Medical Innovations, Response Biomedical, Roche Diagnostics, Abbott Diagnostics, Beckman Coulter, Ortho-clinical Diagnostics, Nanogen, biomérieux, Axis-Shield, Lifesign, and Prognostics.

"Cardiac Biomarkers: A Global Strategic Business Report" from Global Industry Analysts, Inc. provides a comprehensive review of market trends, drivers, product profile, players, competition, recent developments, mergers, acquisitions, and other strategic industry activities. Analysis is presented for major geographic markets such as the United States, Europe and rest of world. Global and regional analytics are provided in terms of assay test types such as CK-MB, Cardiac Troponin, Myoglobin and BNP & NT-proBNP assay tests. Analytics is also provided in terms of location type such as Laboratory Testing and Point-of-Care Testing (POCT).

For more details about this research report, please visit

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Web Site


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website